Brazilian pharmaceutical firms Eurofarma and EMS are aggressively challenging Novo Nordisk’s dominance in the weight-loss drug sector. Eurofarma has reduced the price of its slimming pens by up to 48%, while Novo Nordisk is pursuing legal action against EMS for alleged trademark violations, according to local media reports.
- Eurofarma slashed prices for its weight-loss pens by up to 48%.
- Novo Nordisk is attempting to block a national rival produced by EMS, citing trademark infringement.
- National versions of weight-loss medications have begun appearing in Brazilian pharmacies.
How Eurofarma is lowering costs for weight-loss medication
Eurofarma has implemented a price reduction of up to 48% for its slimming pens, according to local media reports. This move targets the market for GLP-1 receptor agonists, a class of drugs used for diabetes and weight loss. One specific product, often referred to in local reports as the Brazilian Wegovy
, is now nearly 50% cheaper than previous pricing, according to reports from Brazilian news outlets.
The price drop increases accessibility to these treatments, which have historically been expensive for the general population. By cutting costs by nearly half, Eurofarma is positioning its national alternative as a more affordable option compared to imported versions of similar medications.
Why Novo Nordisk is suing EMS over branding
The manufacturer of Ozempic, Novo Nordisk, is taking legal action to prevent the entry of a national competitor produced by EMS. The company alleges that EMS violated its trademarks in the branding of its rival weight-loss drug, according to reports from local Brazilian media.
Novo Nordisk is contesting the name used by the Brazilian competitor, arguing that it infringes on the established brand identity of its own products. This legal dispute highlights the tension between the global pharmaceutical giant and domestic manufacturers as the market for weight-loss medications expands in Brazil.
The current availability of national Ozempic alternatives
National versions of medications similar to Ozempic have officially reached pharmacy shelves, according to local media reports. This expansion marks a shift in the market, moving from a reliance on a single global supplier to the introduction of domestic alternatives.
The arrival of these national options, combined with the aggressive pricing strategies seen from companies like Eurofarma, suggests a broader trend of increased competition. This shift typically leads to lower consumer prices and higher availability of specialized medications within the domestic healthcare system.
